Abstract
Abstract. Several studies have been carried out to evaluate the risk of thrombosis when using contraceptive steroids (for reference, see Åstedt 7). The estrogenic component of oral contraceptives (OC) has been held responsible for a thrombogenic effect (18, 22, 31). Similar extensive epidemiologic studies dealing with the risk of thrombosis when using climacteric substitution therapy are not available. However, the Boston Collaborative Drug Surveillance Program (38) was unable to show any relationship between estrogen replacement therapy and thrombosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
